New pill may ease rare blood disorder that attacks in the cold

NCT ID NCT06067048

Ongoing Disease control Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland Source: ClinicalTrials.gov ↗

First seen Apr 02, 2026 · Last updated May 16, 2026 · Updated 4 times

Summary

This study tests a drug called zanubrutinib in 25 people with cold agglutinin disease, a rare condition where the immune system destroys red blood cells, especially in cold weather. The drug targets the cells that make the harmful antibodies. The goal is to see if it can control anemia and cold-related symptoms without the need for stronger chemotherapy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

AZ Delta

Roeselare, Belgium
Amsterdan UMC ( location AMC)

Amsterdam, Netherlands
Erasusmc

Rotterdam, Netherlands
Haukeland University Hospital Bergen

Bergen, Norway
Odense University Hospital

Odense, Denmark
Oslo University Hospital

Oslo, Norway
Rigshospitalet

Copenhagen, Denmark
UMCG

Groningen, Netherlands
UZ leuven

Leuven, Belgium
st. Olavs Hospital

Trondheim, Norway

Conditions

Explore the condition pages connected to this study.

LYMPHOMA